Unknown

Dataset Information

0

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.


ABSTRACT:

Introduction

Valoctocogene roxaparvovec is an investigational AAV5-based factor VIII (FVIII) gene therapy that has demonstrated sustained clinical benefit in people with severe haemophilia A.

Aim

To report safety, tolerability, efficacy, and quality of life (QOL) among participants who received valoctocogene roxaparvovec in a phase 1/2 clinical study (NCT02576795).

Methods

Men ≥18 years of age with severe haemophilia A (FVIII ≤1 IU/dl) without history of FVIII inhibitors or anti-AAV5 antibodies received a single infusion of valoctocogene roxaparvovec and were followed for 5 years (6 × 1013 vg/kg dose, n = 7) and 4 years (4 × 1013 vg/kg dose, n = 6).

Results

Over the past 2 years, few adverse events and no FVIII inhibitors were reported. Per chromogenic substrate (CSA) assay at years 5 and 4, four of seven and three of six participants in the 6 × 1013 and 4 × 1013 vg/kg cohorts, respectively, maintained median FVIII levels >5 IU/dl, corresponding to mild haemophilia. By regression analysis, rate of change in FVIII activity was -0.14 (95% confidence interval [CI]: -.32 to .03) IU/dl/wk in the 6 × 1013 vg/kg cohort in year 5 and -.06 (95% CI: -.14 to .01) IU/dl/wk in the 4 × 1013 vg/kg cohort in year 4. No participants resumed FVIII prophylaxis, and eight of 13 participants reported zero bleeds in the past 2 years. Improved QOL from baseline persisted in the 6 × 1013 vg/kg cohort; all six Haemo-QOL-A domain scores increased. For the 4 × 1013 vg/kg cohort, high baseline Haemo-QOL-A scores persisted.

Conclusion

These results demonstrate transgene expression and haemostatic response for up to 5 years in individuals with haemophilia A.

SUBMITTER: Pasi KJ 

PROVIDER: S-EPMC9291073 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7192367 | biostudies-literature
| S-EPMC6463803 | biostudies-literature
| S-EPMC6517302 | biostudies-literature
| S-EPMC4942841 | biostudies-literature
| S-EPMC7212083 | biostudies-literature
| S-EPMC6825592 | biostudies-literature
| S-EPMC6244035 | biostudies-other
| S-EPMC6069878 | biostudies-literature
| S-EPMC6852207 | biostudies-literature
| S-EPMC7894464 | biostudies-literature